Disease relevance of Dimetindene

• A new antihistamine hc20-511 compared with dimetinden (fenistil retard) in the treatment of chronic urticaria and other pruritic dermatoses [1].

High impact information on Dimetindene

• Cells were diluted 1:10 in culture medium and incubated with a placebo formulation (PLAC), containing 0.022% benzalkonium chloride, which was part of all formulations, a registered 2% formulation of DNCG, a 0.1% formulation of DMM, and a registered 0.1% formulation of AZL [2].
• 12 h before a 4-hour continuous challenge with permanent 1,000 Dactylis grass pollen/m3 of air in the VCC, 4 or 8 mg of dimethindene (Fenistil pellets) or an identically appearing placebo was administered in three sessions [3].
• The changes evoked by ischaemia and reoxygenation were significantly attenuated by addition of fenistil (histamine H1 receptor antagonist) [4].
• Effect-kinetic characterization of dimethindene maleate following oral administration (Fenistil, Tropfen) [5].
• The efficacy of topical dimethindene maleate (DMM, CAS 31614-69-5, Fenistil Gel) in the treatment of sunburn was evaluated in a placebo-controlled, 1-period crossover trial in 24 healthy volunteers [6].

Analytical, diagnostic and therapeutic context of Dimetindene

• Capillary electrophoresis (CE) has been used for the chiral resolution of the basic racemic drug dimethindene (Fenistil) and its metabolite N-demethyl-dimethindene [7].

References